compounded semaglutide fda warning november 2025 issued 25 letters to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of fda semaglutide compounding warning november

The nitratenitritenitric oxide (NO) pathway offers a high dose of nitrates

While dietary supplements are less tightly regulated than drugs, the FDA still requires them to only contain ingredients found on a list of approved substances

Xu D, Ran Q, Xiang Y, Jiang L, Smith BM, Bou-Abdallah F, et al

They argue that the cost-effectiveness estimates for semaglutide are within the range that NICE considers an acceptable use of NHS resources. As a result, NHS England is required to fund treatment within 90 days

Final Thoughts GLP-1 medications are available in Canada and play an important role in managing type 2 diabetes and supporting medical weight management for eligible patients